Streetbeat News

Stock Prices

A

DHR

Agilent Technologies, Inc. (A) shares are trading higher, potentially in response to Danaher Corporation's (DHR) better-than-expected Q1 financial results. This movement suggests that investors may be optimistic about Agilent's prospects, given the positive performance of a similar company in the sector.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:48 pm

CRL

DHR

Charles River shares are trading higher, potentially in response to Danaher's better-than-expected Q1 financial results, suggesting a sympathetic market movement.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:47 pm

PKG

Packaging Corporation of America's shares declined following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:46 pm

DGX

Quest Diagnostics shares surged following a Q1 earnings beat and an upward revision of its 2024 guidance.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:45 pm

FRAF

Franklin Financial Servs (NASDAQ:FRAF) reported a Q1 EPS of $0.77, up 2.67% YoY, with sales increasing 10.45% to $17.74M from $16.06M YoY.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:44 pm

KULR

KULR Technology Group Inc. has received an order for deploying its power cell battery technology in AI-enabled drones and air mobility missions in Ukraine. This development highlights KULR's involvement in providing critical technology for unmanned aerial vehicles (UAVs) in conflict zones, potentially increasing its visibility and demand in defense and commercial sectors.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:39 pm

AGEN

MPLN

The article highlights MultiPlan Corporation (NYSE:MPLN) and Agenus Inc. (NASDAQ:AGEN) as the top 2 oversold health care stocks, suggesting potential investment opportunities. MPLN announced its Q1 2024 financial results release for May 8, 2024, after a recent 18% stock decline. AGEN reported positive Phase 1 trial results for a cancer therapy, following a 48% stock decrease over the past month. Both stocks have an RSI below 30, indicating they may be undervalued.

Portfolio Pulse from Avi Kapoor

April 23, 2024 | 12:36 pm

ABEO

CDNS

IBRX

Abeona Therapeutics' stock plummeted by 55% following an FDA Complete Response Letter for pz-cel, Cadence Design System shares dropped 10% due to weak Q2 guidance, and ImmunityBio surged 41% after receiving FDA approval for ANKTIVA for bladder cancer.

Portfolio Pulse from ryanfaloona@benzinga.com

April 23, 2024 | 12:35 pm

PALI

Palisade Bio's stock is trading higher following the announcement of a collaboration with Strand Life Sciences, indicating a positive market response to the partnership.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:34 pm

OND

SOCL

SPOT

Spotify Technology SA (NYSE:SPOT) reported a 20% year-on-year revenue growth for Q1 2024, reaching €3.64 billion ($3.95 billion), surpassing the consensus of $3.85 billion. EPS was €0.97 ($1.05), beating the consensus of $0.70. Premium revenue and subscribers grew by 20% and 14% respectively, with ARPU increasing by 5%. However, total MAUs of 615 million fell short of guidance by 3 million. The company cited moderated marketing activity and recent layoffs as factors. Ad-supported MAUs and revenue saw significant growth. Gross margin improvements were noted across the board, with operating income hitting a new quarterly high of €168 million. Spotify expects Q2 revenue of €3.8 billion and 631 million MAUs. SPOT shares rose 8.27% in premarket trading. Investors can also gain exposure through Global X Social Media ETF (NASDAQ:SOCL) and ProShares On-Demand ETF (NYSE:OND).

Portfolio Pulse from Anusuya Lahiri

April 23, 2024 | 12:33 pm